Valuation: Inhalation Sciences Sweden AB

Market Cap 12.08M 1.25M 1.1M 1.01M 938K 1.78M 119M 1.81M 4.7M 58.63M 4.7M 4.6M 202M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 9.25M 959K 839K 771K 718K 1.36M 91.33M 1.38M 3.6M 44.89M 3.6M 3.52M 155M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 day-0.84%
1 week+4.89%
Current month+0.85%
1 month+7.27%
3 months-17.48%
6 months-94.56%
Current year-94.56%
1 week 0.2
Extreme 0.204
0.24
1 month 0.19
Extreme 0.1925
0.24
Current year 0.17
Extreme 0.172
0.58
1 year 0.17
Extreme 0.172
0.58
3 years 0.17
Extreme 0.172
4.99
5 years 0.17
Extreme 0.172
11.3
10 years 0.17
Extreme 0.172
15.48
Manager TitleAgeSince
Chief Executive Officer - 2019-09-15
Chief Tech/Sci/R&D Officer - 2004-12-31
Corporate Officer/Principal - 2025-06-01
Director TitleAgeSince
Director/Board Member - 2004-12-31
Director/Board Member - 2022-08-31
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.84%+4.89%-94.56%-92.13% 1.25M
+1.97%+2.03%+21.92%+0.83% 195B
+5.87%+5.27%-21.76%+26.78% 151B
+2.17%+0.89%-2.59%-16.42% 140B
+4.83%+2.06%-56.73%-15.69% 67.09B
+2.59%+3.95%+22.89%+3.15% 54.34B
+0.03%+2.19%-25.17%-31.30% 44.63B
+0.31%+1.30%+8.30%+43.25% 37.24B
-2.02%-3.91%+7.67%+9.53% 36.91B
+4.24%+4.66%-18.42%-2.34% 30.24B
Average +1.91%+2.30%-15.84%-7.43% 75.59B
Weighted average by Cap. +2.78%+3.44%-4.01%+2.00%

Financials

2024 2025
Net sales 11.05M 1.15M 1M 920K 858K 1.63M 109M 1.65M 4.29M 53.61M 4.3M 4.21M 185M 3.04M 315K 276K 253K 236K 448K 30.02M 455K 1.18M 14.76M 1.18M 1.16M 50.85M
Net income -5.15M -534K -467K -429K -400K -758K -50.81M -769K -2M -24.98M -2M -1.96M -86.07M -10.16M -1.05M -921K -846K -789K -1.5M -100M -1.52M -3.95M -49.3M -3.95M -3.87M -170M
Net Debt -4M -415K -363K -333K -311K -590K -39.52M -598K -1.56M -19.43M -1.56M -1.52M -66.94M -2.83M -294K -257K -236K -220K -417K -27.95M -423K -1.1M -13.74M -1.1M -1.08M -47.34M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
26-07-03 SEK 0.2360 -0.84% 36,557
26-07-02 SEK 0.2380 +15.53% 5,742
26-07-01 SEK 0.2060 -11.97% 2,945
26-06-30 SEK 0.2340 -2.50% 527,733
26-06-29 SEK 0.2400 +6.67% 51,363

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock